Teva’s commercial advantage from being the sole rituximab biosimilar sponsor with a rheumatoid arthritis indication has been blunted. Amgen’s Riabni (rituximab-arrx) has been approved for the same inflammatory joint disease indication by the US Food and Drug Administration.
Already approved for the treatment of adult patients with non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, Wegener’s granulomatosis and microscopic polyangiitis, Riabni’s approval for moderate to severely active rheumatoid arthritis means
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?